The Australia based Sienna’s hTERT test help urologists to detect bladder cancer earlier, and thereby improve patient welfare and lower overall costs in the healthcare system.
This new distribution agreement will broaden and accelerate the global roll out of Sienna’s hTERT IVD test.
Additionally, the agreement provides Axlab with the right to sell Sienna’s product to pathology laboratories.
Axlab is a Denmark based experienced supplier of instruments, reagents and consumables for histology and cytology.
Sienna plans to penetrate its products into the Nordic market using Axlab’s existing facilities and significant knowledge in cytology.
Sienna's primary platform is the detection of the biomarker telomerase, which is found in nearly all epithelial cancers, and was the subject of a Nobel Prize in 2009.
The regulation of telomerase activity in human cells plays a significant role in the development of cancer.
Importantly, clinical pathology laboratories in the region may now purchase Sienna’s IVD product to detect the presence of hTERT, a component of telomerase.